Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Labelled Phase III Adjuvant Trial of Disease-free Survival in Patients With Resected Pancreatic Ductal Adenocarcinoma Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature

NCT05314998 is registered in ClinicalTrials.gov with John Neoptolemos as lead sponsor.

NCT NCT05314998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05314998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Labelled Phase III Adjuvant Trial of Disease-free Survival in Patients With Resected Pancreatic Ductal Adenocarcinoma Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature
Lead sponsor
John Neoptolemos
Phase
Phase 3
Overall status
Recruiting
Start date
August 17, 2026
Completion date
September 1, 2034
Enrollment
394 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma